Track topics on Twitter Track topics that are important to you
RATIONALE: Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with olaparib may kill more tumor cells.
PURPOSE: This randomized phase I/II trial is studying the side effects and the best dose of cediranib maleate when given together with olaparib and to see how well they work compared to cediranib maleate alone in treating patients with recurrent ovarian epithelial cancer, fallopian tube cancer, peritoneal cancer, or recurrent triple-negative breast cancer.
- Assess the maximum-tolerated dose of cediranib maleate in combination with olaparib in patients with recurrent platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer or metastatic triple-negative breast cancer. (Phase I)
- Assess the efficacy, in terms of progression-free survival (PFS), of cediranib maleate with versus without olaparib in patients with recurrent grade 2 or 3 platinum-sensitive papillary-serous ovarian, fallopian tube, or peritoneal cancer. (Phase II)
- Assess the toxicity of this regimen in these patients. (Phase I)
- Assess the clinical benefit, PFS, and overall survival of patients treated with this regimen. (Phase I)
- Assess tumor response, clinical response benefit, and overall survival of patients treated with these regimens. (Phase II)
OUTLINE: This is a multicenter, phase I, dose-escalation study followed by a randomized phase II study.
- Phase I: Patients receive oral cediranib maleate once daily and oral olaparib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
- Phase II: Patients are stratified according to prior antiangiogenic therapy (yes vs no) and BRCA mutation status (carrier vs non-carrier vs unknown). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral cediranib maleate once daily on days 1-28.
- Arm II: Patients receive oral cediranib maleate once daily and oral olaparib twice daily on days 1-28.
In both arms, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 3 years.
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
cediranib maleate, olaparib
Not yet recruiting
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:13:59-0400
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surger...
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib an...
This randomized phase II trial studies how well olaparib, cediranib maleate, and Wee1 inhibitor AZD1775 work in treating patients with endometrial cancer that has come back, does not respo...
This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back. Cediranib maleate and...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer. Drugs used in chemotherapy, su...
Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic ...
The poly(ADP-ribose) polymerases (PARPs) 1 and 2 are DNA-binding enzymes that play a critical role in the repair of DNA. The use of PARP inhibitors is a rational therapeutic approach to selectively ki...
Inhibition of Poly (ADP-ribose) polymerase (PARP) has shown marked benefit for breast cancer with homologous recombination deficiency, whether driven by defects in BRCA1, BRCA2, or other pathway compo...
Gene expression profiling of breast cancer has demonstrated the importance of stromal response in determining the prognosis of invasive breast cancer. The host response to breast cancer is of increasi...
The aim of this study was to assess the frequency of second primary non-breast cancer after breast cancer diagnosis and treatment, and its correlation with clinicopathological features.
Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).
Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...